Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, ...

ERS Genomics Limited ('ERS Genomics'), the CRISPR licensing company, today announced that it has signed a non-exclusive ...

A 2026 review summarizes advances in CRISPR-Cas9 precision, delivery and primary-cell engineering for genetic diseases and ...

CRISPR Therapeutics has seen its share price under pressure in recent years, even as fresh clinical data like the planned ...

CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data from the Phase 1b trial of CTX310 ®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related ...

Vancouver, Oct. 18, 2023 (GLOBE NEWSWIRE) -- The global CRISPR/CAS 9 technology market size is expected to reach USD 13,072.73 Million at a steady revenue CAGR of 20.4% in 2032, according to latest ...

Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...

In a study published in MedComm—Biomaterials and Applications Professor Changyang Gong and his Ph.D. student Shiyao Zhou elaborate on the mechanism of CRISPR/Cas9 system. The CRISPR/Cas9 system ...

Gene editing, also known as genome editing, allows scientists to modify the DNA of organisms using biotechnological techniques. CRISPR-Cas9 is the most widely used gene editing technology, known for ...

AI executives are betting big on biology. They say their large language models that have already dramatically changed the fields of coding and software development and mathematics can upend biological ...

AI giant announces discovery amid global debate about how to safeguard against catastrophic risks.

Update: On 8 December, the US Food and Drug Administration approved the CRISPR–Cas 9 therapy for sickle cell disease described in this story. Less than a month after the world’s first approval of a ...